DIG Trial

Summary: Evaluated digoxin versus placebo in heart failure patients (EF < 45%) and sinus rhythm. The primary endpoint of all-cause mortality was not reduced with digoxin, however hospitalization was reduced. There was no mortality or hospitalization benefit if the EF was > 45% (subtrial).

Original Publication:

N Engl J Med. 1997 Feb 20;336(8):525-33.

Eponym: Digitalis Intervention Group trial